Invention Grant
- Patent Title: Assays and methods for selecting a treatment regimen for a subject with leukemia
-
Application No.: US17173677Application Date: 2021-02-11
-
Publication No.: US11746386B2Publication Date: 2023-09-05
- Inventor: Max Gordon , Paul Tardi , Jeffrey Tyner , Lawrence Mayer
- Applicant: Celator Pharmaceuticals, Inc. , Oregon Health & Science University
- Applicant Address: US CA Palo Alto
- Assignee: CELATOR PHARMACEUTICALS, INC.,OREGON HEALTH & SCIENCE UNIVERSITY
- Current Assignee: CELATOR PHARMACEUTICALS, INC.,OREGON HEALTH & SCIENCE UNIVERSITY
- Current Assignee Address: US CA Palo Alto; US OR Portland
- Agency: Morgan, Lewis & Bockius LLP
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886 ; A61K31/5377 ; A61K31/704 ; A61K31/7068 ; C12Q1/68 ; A61K31/4709 ; A61K31/517 ; A61K31/496 ; A61K31/44 ; A61K31/506 ; A61K31/553 ; A61P35/02 ; A61K9/127 ; A61K31/407
Abstract:
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
Public/Granted literature
- US20210246512A1 ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA Public/Granted day:2021-08-12
Information query
IPC分类:
